

REMARKS

Claims 1-54 are pending in this application.

Rejection Under 35 U.S.C. 112, second paragraph

The Examiner has rejected Claim 6 as being indefinite because "v" is allegedly undefined. The claim has been amended to replace "v" with "V". The term "V" is defined in part "(h)" of the claim. Reconsideration and withdrawal of this rejection in view of this amendment is respectfully solicited.

Rejection Under 35 U.S.C. 102(b)

Claims 1, 3, and 4 have been rejected under 35 U.S.C. 102(b) as being allegedly anticipated by Rychnovsky (J. Org. Chem., 1991, Vol. 56, pp 5161-5169). Claim 1 has been amended to require that in the "L" group, n is an integer from 1 to 5. With this amendment, W can no longer be a t-butyl group and thus Rychnovsky does not anticipate the present application under 35 U.S.C. 102(b). This amendment is supported by the statement on page 22 that "L is $C(R^1)(R^2)-(CH_2)_n-Y$, where n is an integer ranging from 0 to 5..." The integers from 0 to 5 are 0, 1, 2, 3, 4, and 5. Accordingly, "n" may be selected from the integers 1, 2, 3, 4, and 5. Reconsideration and withdrawal of this rejection in view of this amendment is respectfully requested.

It is respectfully submitted that the claims have been put in condition for allowance. Notification to this affect is earnestly solicited. The Examiner is encouraged to contact the Applicants' undersigned attorney to discuss this matter if any questions should arise upon further examination of the pending claims.

Respectfully submitted,

Date: MAY 21, 2007

John H. Engelmann
John H. Engelmann
Reg. No. 28,075
Pfizer Inc.
7000 Portage Road
Kalamazoo, MI 49001
Tel. (269) 833-2532
Fax (269) 833-8897